Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy

Introduction: Gliomas consist of a very heterogeneous group of malignant tumors, accounting for 50 - 60% of primary brain tumors. Despite all the efforts of cytoreductive surgery in combination with intense chemoradiotherapy, glioblastoma multiforme (GBM, glioma grade IV) still has a dismal prognosis. Current research is focused on molecular targeting to overcome resistance to conventional therapy. MicroRNAs (miRNAs), small non-coding RNAs, represent endogenous agents of RNA interference, dramatically changing expression of target proteins. Their role in brain physiology as well as GBM development has attracted intense research efforts pointing toward therapeutic potential and immediate targeting for sensitization of glioma cells to chemo and/or radiotherapy. Areas covered: This review is focused on the variable role of miRNAs in gliomagenesis and their possible clinical relevance in patient's survival and prognosis. It further addresses the potential application of selected miRNAs as therapeutic targets or agents in GMB, including data from clinical studies in other central nervous system tumors. Expert opinion: Although miRNA-targeted therapy is still in its initial stage and clinical trials with glioma/brain tumor patients are under recruitment or currently running, several miRNAs have been selected as promising tumor biomarkers, with increased potential to reduce disease progression in combination to conventional first-line therapy for gliomas.